SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration showing open hands underneath people inside circle shape
Career Advice
Stoicism in the Workplace: Old Philosophies in a New Light
Gratitude, a key part of stoicism, can benefit those working in—and being served by—the pharmaceutical industry.
December 18, 2024
 · 
4 min read
 · 
Jill Marie Drury
FDA sign in front of its building in Maryland
GLP-1
FDA Issues Warning Letters Against Online GLP-1 Sellers
The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision to end the shortage for tirzepatide.
December 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Cardiovascular disease
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data
Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the Phase Ib/II trial than in preclinical models, according to William Blair analysts.
December 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
Biopharma’s Manufacturing Push and Other 2024 Trends
The Novo-Catalent deal now moving ahead highlights unprecedented investment in manufacturing, while also standing out as an exception to the unspoken rule of keeping M&As to less than $5 billion this year.
December 18, 2024
 · 
1 min read
 · 
Jef Akst
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Business
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop
The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year of consistent share value decline, analysts remain skeptical.
December 17, 2024
 · 
3 min read
 · 
Kate Goodwin
Extreme Close-Up Of Human Eye
Postmarket research
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.
December 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Feb 2, 2020 South San Francisco / CA / USA - Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Pipeline
Merck Axes Two Cancer Candidates After Disappointing Late-Stage Results
Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage failures.
December 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Johnson & Johnson Business Center in Switzerland
Complete response letters
J&J’s FDA Bid for Subcutaneous Rybrevant Falls Short
The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with the regulator to resolve these problems.
December 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration shows leader watering employees on branch
Leadership
Leading From the Front: 3 Leadership Lessons From Mark Cuban
Businessman and entrepreneur Mark Cuban recently discussed leadership with Leadership Lab columnist Michael Pietrack. The three lessons that came out of that conversation start with one word: caring.
December 17, 2024
 · 
6 min read
 · 
Michael Pietrack
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS